Neuropsychological effects of interferon ?-1a in relapsing multiple sclerosis-Reference-Cited by-同舟云学术

Neuropsychological effects of interferon ?-1a in relapsing multiple sclerosis

Published:2000-12 Issue:6 Volume:48 Page:885-892
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Fischer Jill S.,Priore Roger L.,Jacobs Lawrence D.,Cookfair Diane L.,Rudick Richard A.,Herndon Robert M.,Richert John R.,Salazar Andres M.,Goodkin Donald E.,Granger Carl V.,Simon Jack H.,Grafman Jordan H.,Lezak Muriel D.,O'Reilly Hovey Kathleen M.,Kawczak Perkins Katherine,Barilla-Clark Danielle,Schacter Mark,Shucard David W.,Davidson Anna L.,Wende Karl E.,Bourdette Dennis N.,Kooijmans-Coutinho Mariska F.,

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference52 articles.

1. Principles of neurology. 6th ed. New York: McGraw-Hill, 1997

2. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis

3. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis

4. Axonal Transection in the Lesions of Multiple Sclerosis

5. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis.

Cited by 260 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review;Frontiers in Neurology;2023-07-12

2. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results;Multiple Sclerosis and Related Disorders;2023-05

3. Instruments measuring change in cognitive function in multiple sclerosis: A systematic review;Brain and Behavior;2023-04-16

4. Review on theranostic and neuroprotective applications of nanotechnology in multiple sclerosis;Journal of Drug Delivery Science and Technology;2023-03

5. Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression;Cellular and Molecular Neurobiology;2021-10-25